Price History

Hover for the daily close. The dotted line marks the period open.

Compare TECX with… →

TECX Key Statistics

As of Sep 4, 2026

Trading

Open: $29.85
Previous Close: $29.92
Day's Range: 29.74–31.12
52-Week Range: 14.39–39.53
Volume: 159.30K
Beta: 0.22

Valuation

Market Cap: $601.14M
P/E Ratio: unprofitable
EPS (ttm): −4.57

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$74.15M
Profit margin: 0.00%
Shares Outstanding: 19.55M
1-Year Return: +78.05%

Dividend and dates

Earnings Date: November 5, 2026estimated
Avg Volume: 199.19K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TECX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−81.56%+182.90%+47.41%

2018*20192020202120222023202420252026*

Year	Return
2026 (partial year)	+47.41%
2025	−54.82%
2024	+182.90%
2023	+91.55%
2022	−81.56%
2021	−72.38%
2020	−30.75%
2019	+20.90%
2018 (partial year)	−46.63%

As of September 4, 2026.

TECX Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$74.15M	—
2024	$0.00	−$57.98M	—
2023	$0.00	−$42.82M	—
2022	$0.00	−$32.18M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$84.04M	−$74.15M	—
2024	$0.00	—	−$58.02M	−$57.98M	—
2023	$0.00	—	−$44.65M	−$42.82M	—
2022	$0.00	—	−$32.83M	−$32.18M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TECX Valuation vs Biotechnology Median

Median of 656 stocks

Metric	TECX	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Tectonic Therapeutic, Inc. (TECX) carries a market capitalisation of $601.14M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 60.

TECX last closed at $30.75 on September 4, 2026. That is +$0.83 (+2.77%) against the previous close. The 52-week range on file runs from $14.39 to $39.53. The latest close sits 113.69% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $74.15M. Profit margin runs at 0%. Trailing earnings per share are −4.57.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year price return is +78.05%. Across 5 years the annualized return works out at −16.39%. Beta against the wider market is reported at 0.22. Annualized volatility over the trailing 8 years is 386.92%.

Growth & Income

The record shows no dividend for TECX.

2026 is still running; the price is +47.41% year to date. The strongest complete calendar year on file is 2024 at +182.90%; the weakest is 2022 at −81.56%. Of the 7 complete calendar years on file, 3 finished higher.

Peer Comparison

Tectonic Therapeutic, Inc. (TECX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Tectonic Therapeutic, Inc.	TECX	$601.14M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Tectonic Therapeutic, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Tectonic Therapeutic, Inc.

Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.

Visit website →

Tectonic Therapeutic, Inc. (TECX) Stock Analysis